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fants reported to CRIMS from 2012 to 2015 suggests a positive
effect of the new policy of immediate ART initiation.
This study was limited to the information available in
CRIMS, and there was potential for bias related to infant death
and loss to follow-up prior to entry into CRIMS as well as un-
equal observed time for participants. However, we provide evi-
dence of a long delay in CRIMS reporting was associated with
profoundly reduced effect on survival. Policymakers should con-
sider integrating follow-up, EID, and ART initiation into pre-
vention of mother-to-child transmission programs to address
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COMMENT & RESPONSE
Errors in Data Input in Meta-analysis on Association
Between Initial Use of e-Cigarettes and Subsequent
Cigarette Smoking Among Adolescents
and Young Adults
To the Editor I write on behalf of my coauthors to report errors
in our article, “Association Between Initial Use of e-Cigarettes
and Subsequent Cigarette Smoking Among Adolescents and
Young Adults: A Systematic Review and Meta-analysis,” that
was published online on June 26, 2017, and in the August
issue of JAMA Pediatrics.1
First, we had inadvertently input incorrect transition prob-
abilities of cigarette smoking initiation by e-cigarette use sta-
tus and, as a result, the wrong unadjusted odds ratio of this
initiation from the study by Leventhal et al.2 After using the
correct data, the correct pooled transition probabilities for ciga-
rette smoking initiation equaled 23.2% for ever e-cigarette us-
ers and 7.2% for never e-cigarette users across all studies (not
the originally reported 30.4% for ever e-cigarette users and
7.9% for never e-cigarette users). In addition, the correct pooled
unadjusted odds ratio of cigarette smoking initiation by ever
e-cigarette use equaled 3.83 (95% CI, 3.74-3.91) across all stud-
ies (not the originally reported 5.12 [95% CI, 4.41-5.95]).
Second, we discovered an error in the statistical code to
input the adjusted odds ratio for the study by Primack et al.3
After using the correct data, the correct pooled adjusted odds
ratio of cigarette smoking initiation from the meta-analysis
equaled 3.50 (95% CI, 2.38-5.16) across all studies (not the origi-
nally reported 3.62 [95% CI, 2.42-5.41]).
However, the conclusions and interpretations of the ar-
ticle were not affected by these errors or the corrections. As
we concluded, “e-cigarette use was associated with greater risk
for subsequent cigarette smoking initiation and past 30-day
cigarette smoking.”1(p788)
We have included a new eTable in the Supplement (eTable
10) that identifies the source of specific input data (eg, ad-
justed odds ratio) for each study. We confirm that there are no
other errors in the originally published article. We have re-
quested that the article be corrected.4 We apologize to JAMA
Pediatrics and its readers for any inconvenience or confusion
our errors may have caused.
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Hypertonic Saline and Acute Bronchiolitis:
The Debate Is Still On
To the Editor We read with interest the study “Effect of Nebu-
lized Hypertonic Saline Treatment in Emergency Depart-
ments on the Hospitalization Rate for Acute Bronchiolitis: A
Randomized Clinical Trial” by Angoulvant et al and the Effi-
cacy of 3% Hypertonic Saline in Acute Viral Bronchiolitis
(GUERANDE) Study Group.1 We thank the authors for this well-
designed and clinically important randomized clinical trial. The
authors concluded that hypertonic saline administration for
bronchiolitis does not reduce hospital admission.
However, we would like to highlight a few important issues.
First, the study was powered to detect a 10% difference in admis-
sion. However, given the prevalence of the disease, would a
smaller reduction in admission rate also be clinically significant?2
This of course would require a more resource-intense study.
We noted with interest that the Respiratory Distress As-
sessment Instrument score improved in the group receiving
hypertonic saline. This may indicate a clinical improvement
in symptoms that may not be reflected in the primary out-
come of hospital admission. Given that admission criteria for
bronchiolitis may differ between centers (or even between phy-
sicians), would reporting a more consistent variable, such as
total hospital length of stay, be more pertinent to this clinical
scenario? At this time, it is not clear which is the most appro-
priate clinical outcome to report for studies of acute treat-
ment of bronchiolitis.
In addition, we also noted that 12.4% of patients (hyper-
tonic saline group) and 9.9% of patients (normal saline group)
tested negative for respiratory syncytial virus. It is possible that
some of these patients have an alternative diagnosis, reduc-
ing the difference in true clinical effect seen from treatment with
hypertonic saline for bronchiolitis. A sensitivity analysis, in-
cluding only respiratory syncytial virus–positive cases, could
help to determine whether this is a clinically important issue.
Again, we appreciate the difficulty and effort required to
conduct such a large-scale randomized trial. We would look
forward to any additional analysis or comments the authors
could provide regarding the issues mentioned here.
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In Reply We thank Tanguay-Rioux et al for their careful read-
ing and response, which allows us to clarify some points of our
study. First, given the burden of acute bronchiolitis in in-
fants, a treatment reducing hospital admission even by few per-
centage points should not be neglected. However, as stated by
Ralston,1 demonstrating a slight efficacy in the experimental
conditions of a randomized clinical trial does not imply a clini-
cal pertinence in daily practice. For example, in a random-
ized clinical trial, patients are enrolled based on rigorous cri-
teria, while a much larger phenotype of patients will be met
in daily practice. The same applies to where and how the treat-
ment is delivered. This point associated with adverse effects,
and the cost of hypertonic saline (HS) nebulizations makes the
clinical utility of such treatment very unlikely.
Second, we agree that both total hospital length and hos-
pital admission are appropriate clinical outcomes to report in
studies of acute treatment bronchiolitis. Indeed, these 2 cri-
teria do not concern the same patients because total hospital
length is only pertinent with the most severe patients, those
requiring hospitalization. Thus, it is possible that a treatment
could have a measurable effect in only 1 of these criteria, mak-
ing their study complementary and not opposed. Concerning
HS nebulization, it failed to prove efficacy in both hospital ad-
mission rate2 and total hospital length.3
Third, as noticed by Tanguay-Rioux et al, respiratory syn-
cytial virus (RSV)–positive cases were associated with an in-
creasing risk of hospitalization, with an odds ratio of 2.17 (95%
CI, 1.25%-3.78%; P = .005) according to our mixed-effects re-
gression model. As suggested, we performed sensitivity analy-
sis including only RSV-positive cases. By 24 hours, 165 of 327
infants (50.5%) in the HS group were admitted compared with
191 of 344 infants (55.5%) in the normal saline group. The dif-
ference in hospitalization rates between the HS and normal sa-
line groups among RSV-positive cases was not significant ac-
cording to our mixed-effects regression model using the center
as the random effect (risk difference, –5.5%; 95% CI, –11.9% to
0.9%; P = .09). These results indicate that a selection bias
linked to patients with an alternative diagnosis was unlikely.
Furthermore, our results concerning the percentage of RSV-
positive cases (86.4%), total hospital length (mean [SD], 3.7 [2.7]
days), and other characteristics data were in line with previ-
ous randomized clinical trials concerning acute bronchiolitis
strengthening the external validity of our study.3,4
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